The coronavirus (COVID-19) outbreak has caused a significant threat to the global health, resulting in surging fatalities. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are capitalizing on the ongoing coronavirus pandemic to increase its trials with Gene-Eden-VIR/Novirin that holds promising potentials for coronavirus treatment. Gene-Eden-VIR/Novirin is a patented herbal broad-spectrum antiviral treatment that has shown clinical evidence for HPV and cytomegalovirus treatment. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are increasing awareness for Gene-Eden-VIR/Novirin.
Gene-Eden-VIR/Novirin is being currently tested for COVID-19, since coronavirus is closely related to the human Severe Acute Respiratory Syndrome (SARS-CoV), owing to its high sequence identity. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are increasing their trials in several existing drugs that are found effective against RNA viruses such as the coronavirus.
Human papillomavirus (HPV) is one of key drivers responsible for most cervical cancer cases worldwide. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are tapping opportunities in nanotechnology for the treatment of viral infection and cancer. Such efforts of companies are reflecting in revenue growth for human papillomavirus therapeutics. As such, DNA Nano-based drug carriers are being highly publicized, owing to its bioavailability and these drugs are gaining prominence in antiviral and anticancer drugs of the human papillomavirus and cytomegalovirus therapeutics market.
AS1411 is a G-quadruplex (G4)-forming DNA oligonucleotide that is found at high levels on the surface of cancer cells. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics are increasing their efforts in clinical trials for AS1411, since the protein holds promising potentials pharmacology and cancer treatment.
Ganciclovir is considered as the gold standard for active cytomegalovirus treatment. As such, Ganciclovir/Valganciclovir is estimated to dictate the highest revenue among all drugs in the cytomegalovirus therapeutics sector. Hence, companies in the human papillomavirus and cytomegalovirus therapeutics market are increasing their production capabilities of intravenous ganciclovir, especially for immunocompromised patients.
On the other hand, second-line drugs such as Cidofovir and Foscarnet are also being highly preferred in the human papillomavirus and cytomegalovirus therapeutics market. These drugs help to inhibit the viral DNA polymerase over cellular polymerases. Acyclovir is another promising drug used in the treatment of cytomegalovirus and is an approved treatment in the European Union. As such, Europe is anticipated to dictate the second-highest revenue among all regions in the human papillomavirus and cytomegalovirus therapeutics market.
There is a growing demand for vaccines in the human papillomavirus and cytomegalovirus therapeutics market. However, researchers have found that the follow-up time has been relatively short over the years to determine the efficacy of Gardasil and Cervarix vaccines for HPV treatment. This explains why the HPV therapeutics sector is estimated to progress at a modest CAGR of ~4% during the forecast period. As such, an unrepresentative population of women older than the usual target age group of 9-13 years is also hampering growth of the human papillomavirus and cytomegalovirus therapeutics market.
Vaccines meant to treat cervical cancer usually takes decades to develop. Hence, companies in the market for human papillomavirus and cytomegalovirus therapeutics should increase their screening intervals to reduce uncertainty associated with the efficacy of vaccines. Moreover, the demand for vaccines is predicted to rise in the human papillomavirus and cytomegalovirus therapeutics market due to high survival rates of HPV patients. For instance, renowned biotech executive Michael Becker who died last year due to HPV, laid emphasis on the potential of vaccines for the treatment of HPV.
Analysts’ Viewpoint
Gene-Eden-VIR/Novirin is predicted to create a ray of hope for coronavirus therapeutics, owing to its efficacy in HPV and cytomegalovirus treatment. AS1411 is found to be well tolerated in therapeutic activities for DNA Nano-based drug carriers.
Companies in the human papillomavirus and cytomegalovirus therapeutics market are becoming increasingly aware about one dose of HPV vaccine, which is relatively more effective than multiple doses. Prioritizing single-dose vaccination in less privileged countries is generating incremental opportunities for companies, since it eliminates the issue of increased spending associated with multiple doses for cancer patients. However, unrepresentative population and uncertainty in trials for HPV vaccines are inhibiting market growth. Hence, companies should aim at extending their screening intervals and target appropriate age groups to validate the efficacy of HPV vaccines.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Human Papillomavirus and Cytomegalovirus Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Value Chain Analysis
5.2. Pipeline Analysis
5.3. Key Mergers, Acquisitions, and Strategic Partnerships
6. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Class, 2017–2027
6.3.1. Human Papillomavirus Therapeutics
6.3.1.1. Immunomodulators
6.3.1.2. Keratolytics
6.3.1.3. Antineoplastics
6.3.1.4. Sinecatechins
6.3.2. Cytomegalovirus Therapeutics
6.3.2.1. Ganciclovir/Valganciclovir
6.3.2.2. Foscavir(Foscarnet)
6.3.2.3. Cidofovir(Vistide)
6.3.2.4. Letermovir(Prevymis)
6.3.2.5. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2027
7.3.1. Human Papillomavirus Therapeutics
7.3.1.1. Genital Warts
7.3.1.2. Genital Cancer
7.3.1.3. Oral Papillomas
7.3.1.4. Others
7.3.2. Cytomegalovirus Therapeutics
7.3.2.1. Retinitis
7.3.2.2. Gastrointestinal Ulcer
7.3.2.3. Pneumonia
7.3.2.4. Encephalitis
7.3.2.5. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2027
8.3.1. Human Papillomavirus Therapeutics
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. Online Pharmacies
8.3.2. Cytomegalovirus Therapeutics
8.3.2.1. Hospital Pharmacies
8.3.2.2. Retail Pharmacies
8.3.2.3. Online Pharmacies
8.4. Market Attractiveness By Distribution Channel
9. Global Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. North America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017–2027
10.2.1. Human Papillomavirus Therapeutics
10.2.1.1. Immunomodulators
10.2.1.2. Keratolytics
10.2.1.3. Antineoplastics
10.2.1.4. Sinecatechins
10.2.2. Cytomegalovirus Therapeutics
10.2.2.1. Ganciclovir/Valganciclovir
10.2.2.2. Foscavir(Foscarnet)
10.2.2.3. Cidofovir(Vistide)
10.2.2.4. Letermovir(Prevymis)
10.2.2.5. Others
10.3. Market Value Forecast, by Application, 2017–2027
10.3.1. Human Papillomavirus Therapeutics
10.3.1.1. Genital Warts
10.3.1.2. Genital Cancer
10.3.1.3. Oral Papillomas
10.3.1.4. Others
10.3.2. Cytomegalovirus Therapeutics
10.3.2.1. Retinitis
10.3.2.2. Gastrointestinal Ulcer
10.3.2.3. Pneumonia
10.3.2.4. Encephalitis
10.3.2.5. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2027
10.4.1. Human Papillomavirus Therapeutics
10.4.1.1. Hospital Pharmacies
10.4.1.2. Retail Pharmacies
10.4.1.3. Online Pharmacies
10.4.2. Cytomegalovirus Therapeutics
10.4.2.1. Hospital Pharmacies
10.4.2.2. Retail Pharmacies
10.4.2.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Application
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017–2027
11.2.1. Human Papillomavirus Therapeutics
11.2.1.1. Immunomodulators
11.2.1.2. Keratolytics
11.2.1.3. Antineoplastics
11.2.1.4. Sinecatechins
11.2.2. Cytomegalovirus Therapeutics
11.2.2.1. Ganciclovir/Valganciclovir
11.2.2.2. Foscavir (Foscarnet)
11.2.2.3. Cidofovir (Vistide)
11.2.2.4. Letermovir (Prevymis)
11.2.2.5. Others
11.3. Market Value Forecast, by Application, 2017–2027
11.3.1. Human Papillomavirus Therapeutics
11.3.1.1. Genital Warts
11.3.1.2. Genital Cancer
11.3.1.3. Oral Papillomas
11.3.1.4. Others
11.3.2. Cytomegalovirus Therapeutics
11.3.2.1. Retinitis
11.3.2.2. Gastrointestinal Ulcer
11.3.2.3. Pneumonia
11.3.2.4. Encephalitis
11.3.2.5. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2027
11.4.1. Human Papillomavirus Therapeutics
11.4.1.1. Hospital Pharmacies
11.4.1.2. Retail Pharmacies
11.4.1.3. Online Pharmacies
11.4.2. Cytomegalovirus Therapeutics
11.4.2.1. Hospital Pharmacies
11.4.2.2. Retail Pharmacies
11.4.2.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Application
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2027
12.2.1. Human Papillomavirus Therapeutics
12.2.1.1. Immunomodulators
12.2.1.2. Keratolytics
12.2.1.3. Antineoplastics
12.2.1.4. Sinecatechins
12.2.2. Cytomegalovirus Therapeutics
12.2.2.1. Ganciclovir/Valganciclovir
12.2.2.2. Foscavir (Foscarnet)
12.2.2.3. Cidofovir (Vistide)
12.2.2.4. Letermovir (Prevymis)
12.2.2.5. Others
12.3. Market Value Forecast, by Application, 2017–2027
12.3.1. Human Papillomavirus Therapeutics
12.3.1.1. Genital Warts
12.3.1.2. Genital Cancer
12.3.1.3. Oral Papillomas
12.3.1.4. Others
12.3.2. Cytomegalovirus Therapeutics
12.3.2.1. Retinitis
12.3.2.2. Gastrointestinal Ulcer
12.3.2.3. Pneumonia
12.3.2.4. Encephalitis
12.3.2.5. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2027
12.4.1. Human Papillomavirus Therapeutics
12.4.1.1. Hospital Pharmacies
12.4.1.2. Retail Pharmacies
12.4.1.3. Online Pharmacies
12.4.2. Cytomegalovirus Therapeutics
12.4.2.1. Hospital Pharmacies
12.4.2.2. Retail Pharmacies
12.4.2.3. Online Pharmacies
12.5. Market Value Forecast, by Country, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Application
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2027
13.2.1. Human Papillomavirus Therapeutics
13.2.1.1. Immunomodulators
13.2.1.2. Keratolytics
13.2.1.3. Antineoplastics
13.2.1.4. Sinecatechins
13.2.2. Cytomegalovirus Therapeutics
13.2.2.1. Ganciclovir/Valganciclovir
13.2.2.2. Foscavir (Foscarnet)
13.2.2.3. Cidofovir (Vistide)
13.2.2.4. Letermovir (Prevymis)
13.2.2.5. Others
13.3. Market Value Forecast, by Application, 2017–2027
13.3.1. Human Papillomavirus Therapeutics
13.3.1.1. Genital Warts
13.3.1.2. Genital Cancer
13.3.1.3. Oral Papillomas
13.3.1.4. Others
13.3.2. Cytomegalovirus Therapeutics
13.3.2.1. Retinitis
13.3.2.2. Gastrointestinal Ulcer
13.3.2.3. Pneumonia
13.3.2.4. Encephalitis
13.3.2.5. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2027
13.4.1. Human Papillomavirus Therapeutics
13.4.1.1. Hospital Pharmacies
13.4.1.2. Retail Pharmacies
13.4.1.3. Online Pharmacies
13.4.2. Cytomegalovirus Therapeutics
13.4.2.1. Hospital Pharmacies
13.4.2.2. Retail Pharmacies
13.4.2.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Application
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Human Papillomavirus and Cytomegalovirus Therapeutics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2027
14.2.1. Human Papillomavirus Therapeutics
14.2.1.1. Immunomodulators
14.2.1.2. Keratolytics
14.2.1.3. Antineoplastics
14.2.1.4. Sinecatechins
14.2.2. Cytomegalovirus Therapeutics
14.2.2.1. Ganciclovir/Valganciclovir
14.2.2.2. Foscavir (Foscarnet)
14.2.2.3. Cidofovir (Vistide)
14.2.2.4. Letermovir (Prevymis)
14.2.2.5. Others
14.3. Market Value Forecast, by Application, 2017–2027
14.3.1. Human Papillomavirus Therapeutics
14.3.1.1. Genital Warts
14.3.1.2. Genital Cancer
14.3.1.3. Oral Papillomas
14.3.1.4. Others
14.3.2. Cytomegalovirus Therapeutics
14.3.2.1. Retinitis
14.3.2.2. Gastrointestinal Ulcer
14.3.2.3. Pneumonia
14.3.2.4. Encephalitis
14.3.2.5. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2027
14.4.1. Human Papillomavirus Therapeutics
14.4.1.1. Hospital Pharmacies
14.4.1.2. Retail Pharmacies
14.4.1.3. Online Pharmacies
14.4.2. Cytomegalovirus Therapeutics
14.4.2.1. Hospital Pharmacies
14.4.2.2. Retail Pharmacies
14.4.2.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Application
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region15. Competition Landscape
15. Market Player - Competition Matrix (By Tier and Size of companies)
15.1. Market Share/Position Analysis, by Company, 2018
15.2. Company Profiles
15.2.1. Merck & Co., Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Bausch & Lomb Incorporated (Bausch Health Companies, Inc.)
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. AbbVie, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. F. Hoffmann-La Roche Ltd.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5. Company Financials
15.2.5.1. Growth Strategies
15.2.5.2. SWOT Analysis
15.2.6. Mylan N.V.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. Takeda Pharmaceutical Company Limited
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Teva Pharmaceutical Industries Ltd.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Clinigen Group plc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. Pfizer, Inc.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis
15.2.11. Cipla, Inc.
15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.11.2. Company Financials
15.2.11.3. Growth Strategies
15.2.11.4. SWOT Analysis
List of Tables
Table 01: Pipeline Analysis, by Human Papillomavirus Therapeutics
Table 02: Pipeline Analysis, by Cytomegalovirus Therapeutics
Table 03: Key Mergers, Acquisitions, and Strategic Partnerships
Table 04: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 05: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 06: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 07: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 08: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 09: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 10: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 11: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 12: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 13: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 14: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 15: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 16: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 17: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 18: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 19: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 20: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 21: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 22: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 23: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 24: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 25: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 26: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 27: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 28: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 29: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 30: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 31: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 32: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 33: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 34: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 35: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 36: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 37: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 38: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 39: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 40: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 41: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 42: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 43: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 44: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 45: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 46: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 47: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 48: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 49: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027
Table 50: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Application, 2017–2027
Table 51: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 03: Global Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 04: Global Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast, 2017–2027
Figure 05: Global Human Papillomavirus Therapeutics Market Value Share, by Drug Class, 2018
Figure 06: Global Human Papillomavirus Therapeutics Market Value Share, by Application, 2018
Figure 07: Global Human Papillomavirus Therapeutics Market Value Share, by Distribution Channel, 2018
Figure 08: Global Human Papillomavirus Therapeutics Market Value Share, by Region, 2018
Figure 09: Global Cytomegalovirus Therapeutics Market Value Share, by Drug, 2018
Figure 10: Global Cytomegalovirus Therapeutics Market Value Share, by Application, 2018
Figure 11: Global Cytomegalovirus Therapeutics Market Value Share, by Distribution Channel, 2018
Figure 12: Global Cytomegalovirus Therapeutics Market Value Share, by Region, 2018
Figure 13: Global Human Papillomavirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 14: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunomodulators, 2017–2027
Figure 15: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Keratolytics, 2017–2027
Figure 16: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antineoplastics, 2017–2027
Figure 17: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Sinecatechins, 2017–2027
Figure 18: Global Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 19: Global Cytomegalovirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 20: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ganciclovir/Valganciclovir, 2017-2027
Figure 21: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Foscavir (Foscarnet), 2017-2027
Figure 22: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Cidofovir (Vistide), 2017-2027
Figure 23: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Letermovir (Prevymis), 2017-2027
Figure 24: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 25: Global Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019-2027
Figure 26: Global Human Papillomavirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 27: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Genital Warts, 2017–2027
Figure 28: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Genital Cancer, 2017–2027
Figure 29: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral Papillomas, 2017–2027
Figure 30: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2027
Figure 31: Global Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 32: Global Cytomegalovirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 33: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retinitis, 2017-2027
Figure 34: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Gastrointestinal Ulcer, 2017-2027
Figure 35: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pneumonia, 2017-2027
Figure 36: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Encephalitis, 2017-2027
Figure 37: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 38: Global Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Application, 2019-2027
Figure 39: Global Human Papillomavirus Therapeutics Market Value Share, by Distribution Channel, 2018 and 2027
Figure 40: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 41: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 42: Global Human Papillomavirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 43: Global Human Papillomaviruses Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027
Figure 44: Global Cytomegalovirus Therapeutics Market Value Share, by Distribution Channel, 2018 and 2027
Figure 45: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 46: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 47: Global Cytomegalovirus Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027
Figure 48: Global Cytomegalovirus Therapeutics Market Attractiveness, by Distribution Channel, 2019–2027
Figure 49: Global Human Papillomavirus Therapeutics Market Value Share, by Region, 2018 and 2027
Figure 50: Global Human Papillomavirus Therapeutics Market Attractiveness, by Region, 2019–2027
Figure 51: Global Cytomegalovirus Therapeutics Market Value Share, by Region, 2018 and 2027
Figure 52: Global Cytomegalovirus Therapeutics Market Attractiveness, by Region, 2019–2027
Figure 53: North America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 54: North America Human Papillomavirus Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 55: North America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 56: North America Human Papillomavirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 57: North America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 58: North America Human Papillomavirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 59: North America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 60: North America Human Papillomavirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 61: North America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 62: North America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 63: North America Cytomegalovirus Therapeutics Market Value Share Analysis, by Country, 2018 and 2027
Figure 64: North America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Country, 2019–2027
Figure 65: North America Cytomegalovirus Therapeutics Market Value Share, by Drug Class, 2018 and 2027
Figure 66: North America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 67: North America Cytomegalovirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 68: North America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 69: North America Cytomegalovirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 70: North America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 71: Europe Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 72: Europe Human Papillomavirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 73: Europe Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 74: Europe Human Papillomavirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 75: Europe Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 76: Europe Human Papillomavirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 77: Europe Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 78: Europe Human Papillomavirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 79: Europe Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 80: Europe Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 81: Europe Cytomegalovirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 82: Europe Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 83: Europe Cytomegalovirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 84: Europe Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 85: Europe Cytomegalovirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 86: Europe Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 87: Europe Cytomegalovirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 88: Europe Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 89: Asia Pacific Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 90: Asia Pacific Human Papillomavirus Therapeutics Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 91: Asia Pacific Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 92: Asia Pacific Human Papillomavirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 93: Asia Pacific Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 94: Asia Pacific Human Papillomavirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 95: Asia Pacific Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 96: Asia Pacific Human Papillomavirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 97: Asia Pacific Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 98: Asia Pacific Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 99: Asia Pacific Cytomegalovirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 100: Asia Pacific Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 101: Asia Pacific Cytomegalovirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 102: Asia Pacific Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 103: Asia Pacific Cytomegalovirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 104: Asia Pacific Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 105: Asia Pacific Cytomegalovirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 106: Asia Pacific Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 107: Latin America Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 108: Latin America Human Papillomavirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 109: Latin America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 110: Latin America Human Papillomavirus Therapeutics Market Value Share, by Drug Class, 2018 and 2027
Figure 111: Latin America Human Papillomavirus Therapeutics Market Attractiveness, by Drug Class, 2019–2027
Figure 112: Latin America Human Papillomavirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 113: Latin America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 114: Latin America Human Papillomavirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 115: Latin America Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 116: Latin America Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 117: Latin America Cytomegalovirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 118: Latin America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 119: Latin America Cytomegalovirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 120: Latin America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 121: Latin America Cytomegalovirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 122: Latin America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 123: Latin America Cytomegalovirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 124: Latin America Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 125: Middle East & Africa Human Papillomavirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 126: Middle East & Africa Human Papillomavirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 127: Middle East & Africa Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 128: Middle East & Africa Human Papillomavirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 129: Middle East & Africa Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 130: Middle East & Africa Human Papillomavirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 131: Middle East & Africa Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 132: Middle East & Africa Human Papillomavirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 133: Middle East & Africa Human Papillomavirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 134: Middle East & Africa Cytomegalovirus Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 135: Middle East & Africa Cytomegalovirus Therapeutics Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 136: Middle East & Africa Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2019–2027
Figure 137: Middle East & Africa Cytomegalovirus Therapeutics Market Value Share Analysis, by Drug Class, 2018 and 2027
Figure 138: Middle East & Africa Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Drug Class, 2019–2027
Figure 139: Middle East & Africa Cytomegalovirus Therapeutics Market Value Share Analysis, by Application, 2018 and 2027
Figure 140: Middle East & Africa Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Application, 2019–2027
Figure 141: Middle East & Africa Cytomegalovirus Therapeutics Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 142: Middle East & Africa Cytomegalovirus Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2019–2027
Figure 143: Market Position/Ranking Analysis, by Tier and Size of the Company, 2018
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Human Papillomavirus and Cytomegalovirus Therapeutics Market
